Latest MD Buyline Report Shows Highest User Satisfaction Composite Ratings for Accuray Incorporated

SUNNYVALE, California, July 17, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that its CyberKnife^® and TomoTherapy^® Systems have received the highest composite overall user satisfaction rating among radiation treatment delivery systems in the U.S., according to the Q2 2014 MD Buyline Market Intelligence Briefing^™. The latest ratings show continuously improving customer satisfaction during the past one-and-a-half years as Accuray demonstrated significant and sustained improvements.

In rating Accuray, MD Buyline* reports higher scores for system performance, system reliability, service response time and applications training for both the CyberKnife and TomoTherapy Systems, validating the company's focus on service excellence and technology performance. TomoTherapy System users believe that the system is a workhorse, with the report indicating that they "love this system and believe that it is one of the best systems on the market for radiation oncology treatments." CyberKnife System users also conveyed positive experiences, stating that they are "pleased with the level of flexibility the system allows" and that it is a "solid and durable system."

"The composite MD Buyline rating for both our company and our product platforms confirms and validates the efforts we have made to deliver a best-in-class customer experience," said Joshua H. Levine, president and CEO of Accuray. "Our customers require the most precise, effective and efficient radiation therapy products and we are committed to providing exactly that."

MD Buyline, an independent market intelligence organization for the healthcare industry, measures linear accelerator user satisfaction based on evaluations by more than 3,300 hospitals in its member network that use the product every day. Respondents rate how satisfied they are with products from Accuray, Elekta and Varian, using key metrics listed above along with installation and implementation, applications training, and service repair quality. (MD Buyline User Satisfaction Ratings, MD Buyline Market Intelligence Briefing™ Q2 2014) ^© 2014 MD Buyline, All Rights Reserved. Used with Permission 7/10/14.

About Accuray
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to clinical performance, clinical results, future market success and trends, customer satisfaction and adoption of the company's products or services, and the company's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from under the heading "Risk Factors" in the company's report on Form 10-K, which was filed on August 29, 2013, the company's report on Form 10-Q, which was filed on May 7, 2014, and as updated periodically by the company's other filings.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.